AstraZeneca And Daiichi Sankyo To Present Findings Of ENHERTU Showing Clinical Activity In Patients With HER2 Positive Metastatic Breast Cancer And Brain Metastases
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca and Daiichi Sankyo's drug ENHERTU shows promising results in treating HER2 positive metastatic breast cancer with brain metastases, achieving a 61.6% progression-free survival rate at one year in the DESTINY-Breast12 trial.
September 13, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's ENHERTU, in collaboration with Daiichi Sankyo, shows significant clinical activity in treating HER2 positive metastatic breast cancer with brain metastases, achieving a 61.6% progression-free survival rate at one year.
The positive results from the DESTINY-Breast12 trial could enhance AstraZeneca's reputation in oncology, potentially boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80